

## CURRICULUM VITAE ET STUDIORUM

**Dott. Fotios Loupakis**



Fotios Loupakis è **nato** a Pisa il **25/01/1979**, è residente a Padova (tel. +39.328.9634053; e-mail: fotiosloupakis@ioveneto.it, Codice Fiscale LPKFTS79A25G702Y).

### **FORMAZIONE**

Dopo aver conseguito il diploma di **Maturità Scientifica** nel Luglio 1997, si è iscritto alla Facoltà di Medicina e Chirurgia dell'Università di Pisa nell'Anno Accademico 1997/98.

Durante gli anni di studi universitari é stato **allievo interno presso:**

- **U.O. Oncologia Medica** (Prof. A. Falcone) dall'anno accademico 2001/02 fino alla laurea dove ha preparato una **tesi sperimentale dal titolo “Chemioterapia di prima linea del carcinoma coloretale metastatico: studi clinici di fase I-II e di fase III con oxaliplatino, irinotecano, 5-fluorouracile infusione e leucovorin”**
- **Divisione di Farmacologia, Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina** (Prof. M. Del Tacca) nell'anno accademico 2002/03, assistendo e collaborando ad attività di **ricerca traslazionale nel campo della farmacogenomica** in relazione a citotossici e trattamento di neoplasie gastrointestinali.

Si è **laureato in Medicina e Chirurgia presso l'Università di Pisa il 08/10/2003 con voti 110/110 e lode.**

Ha conseguito l'**abilitazione all'esercizio della professione medica** nel Novembre 2003 e si è iscritto all'albo dei medici della provincia di Pisa il 05/02/2004 (N° iscrizione 4732).

Dal Giugno 2004 a Ottobre 2007 ha lavorato in qualità di **specializzando in Oncologia** dell'Università di Pisa presso l'U. O. di Oncologia Medica dell'Ospedale di Livorno diretta dal Prof. A. Falcone collaborando all'assistenza di pazienti oncologici e svolgendo attività scientifica di ricerca in prevalenza nel campo della terapia dei tumori gastrointestinali.

Durante questo periodo ha inoltre conseguito il titolo di **Master Universitario di II Livello in Sperimentazione Clinica dei Farmaci** in data 09/12/2005 presso l'Università di Pisa, Divisione di Farmacologia, Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina.

Ha conseguito la **Specializzazione in Oncologia** presso l'Università degli Studi di Pisa il 29/10/2007 **con punti 110/110 e lode**.

Nel Giugno 2011 ha conseguito il titolo di **Dottorato di Ricerca in "Tecnologie per la salute: valutazione e gestione delle innovazioni nel settore biomedicale"** presso l'Università di Pisa, Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina.

Dal Luglio 2011 al Febbraio 2012 è stato **Research Fellow** presso il laboratorio di Oncologia Traslazionale diretto dal Prof. Heinz-Joseph Lenz, Keck School Of Medicine, University of Southern California, Los Angeles (USA).

#### **ATTIVITA' CLINICO-ASSISTENZIALE**

Nel Luglio 2008 è risultato vincitore di **Concorso pubblico per incarico a tempo indeterminato in qualità di Dirigente Medico in Oncologia** bandito dall'AZIENDA U.S.L. 6 di Livorno dove presta servizio dal Novembre 2008 presso l'U.O. di Oncologia Medica diretta dal Prof. Alfredo Falcone.

Dal 2 Marzo 2009 si è trasferito presso l'U.O. Oncologia Universitaria dell'Azienda Ospedaliero-Universitaria Pisana diretta dal Prof. Alfredo Falcone dove ha ricoperto l'incarico di **Dirigente Medico in Oncologia** fino al 14 Giugno 2016.

Nel Maggio 2012 è nominato **Coordinatore del Gruppo Oncologico Multidisciplinare Neoplasie del Colonretto** del Polo Oncologico di Area Vasta dalla Direzione dell'Azienda Ospedaliero-Universitaria Pisana (incarico ricoperto fino al 14 Giugno 2016).

Dal 15 Giugno 2016 si è trasferito con l'incarico di **Dirigente Medico in Oncologia** presso l'U.O. di Oncologia Medica 1 dell'Istituto Oncologico Veneto, IRCCS diretta dalla Dr.ssa Vittorina Zagonel.

### **ATTIVITA' DIDATTICA**

Dal 1 Gennaio 2010 al 15 Giugno 2016 è **Professore a Contratto** presso la Scuola di Specializzazione di Oncologia Medica e **Cultore della Materia per l'insegnamento di Oncologia Medica** (MED06) presso la Facoltà di Medicina e Chirurgia dell'Università di Pisa e responsabile del Corso di Oncologia nell'ambito dell'insegnamento integrato di Patologia Oncologica Orale

Nel Dicembre 2013 ha conseguito l'**abilitazione per il ruolo di Professore di seconda fascia** - Abilitazione Scientifica Nazionale Bando 2012 - con il superamento delle tre mediane degli indicatori stabiliti (articoli normalizzati: 98,57 - citazioni normalizzate: 202,86 - indice H-C: 18)

### **ATTIVITA' SCIENTIFICA**

A partire dagli anni di studio universitari il Dott. Loupakis si è dedicato allo studio della Oncologia sia sperimentale che clinica, frequentando già prima della laurea l'U.O. di Oncologia Medica dell'Ospedale di Livorno e la Divisione di Farmacologia, Facoltà di Medicina dell'Università di Pisa e preparando una tesi sperimentale sul trattamento del carcinoma coloretale metastatico.

L'attività di ricerca finora svolta è stata sempre orientata verso l'oncologia sia pre-clinica che clinica, con una particolare attenzione al trasferimento degli avanzamenti nel campo della farmacologia e della oncologia sperimentale alla clinica (ricerca traslazionale). In particolare tale attività è stata svolta sia in collaborazione con la Divisione di Farmacologia della Facoltà di Medicina dell'Università di Pisa che con l'Istituto di Biochimica "G. Fornaini" dell'Università di Urbino. Essa si è principalmente concentrata sui seguenti argomenti:

- Studi clinici e traslazionali (fattori predittivi di risposta/tossicità) con farmaci citotossici e con farmaci a bersaglio molecolare specifico.
- Studi clinici e traslazionali con nuove terapie antiangiogeniche, con particolare riguardo a modalità innovative di somministrazione (terapia metronomica).
- Ricerca clinica relativa al trattamento medico di neoplasie solide dell'adulto quali carcinoma gastrico e coloretale.

Sulla base di questa attività di ricerca il Dott. Fotios Loupakis **ha prodotto 148 pubblicazioni in estenso su riviste indicizzate (PubMed) e con Impact Factor e oltre 400 Abstracts** di comunicazioni a congressi nazionali ed internazionali.

**Ha partecipato a oltre 400 Congressi e Corsi** nazionali ed internazionali in qualità di ospite, relatore o moderatore a partire dal 2001.

Ha svolto regolarmente **Attività di Revisore** per riviste scientifiche internazionali indicizzate su banche dati (da 2007 ad oggi): Annals of Oncology; Journal of Clinical Oncology, Lancet Oncology, Clinical Cancer Research, The Pharmacogenomics Journal, British Journal of Cancer, Journal of Cancer Therapeutics and Research, Journal of Oncology, PLOS One, Expert Opinion on Emerging Drugs, Pharmacogenomics, International Journal of Cancer, Pharmacogenetics and Genomics, Biodrugs, Molecular Genetics and Genomics, Carcinogenesis, BMC Cancer.

Ha partecipazione all'ideazione, stesura del protocollo, promozione, conduzione e analisi di oltre 50 studi clinici e/o traslazionali no-profit e indipendenti, di cui i maggiori sono riportati di seguito:

*Studio TRIBE* - A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (TRIBE ASL608LIOM04) EUDRACT 2008-001537-10

*Studio BEBYP* - AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS BEVACIZUMAB (BEBYP ASL607LIOM03 AIFA - FARM5C4FB4) EUDRACT 2007-002886-11

*Studio MACBETH* - INDUCTION CHEMOTHERAPY WITH FOLFOXIRI PLUS CETUXIMAB AND MAINTENANCE WITH CETUXIMAB OR BEVACIZUMAB THERAPY IN UNRESECTABLE KRAS WILD-TYPE METASTATIC COLORECTAL CANCER PATIENTS EUDRACT 2011-000840-70

*Studio MOMA* - PHASE II RANDOMIZED STUDY OF MAINTENANCE TREATMENT WITH BEVACIZUMAB OR BEVACIZUMAB PLUS METRONOMIC CHEMOTHERAPY AFTER FIRST-LINE INDUCTION FOLFOXIRI PLUS BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER PATIENTS EUDRACT 2011-006332-23

In merito alla **partecipazione scientifica a progetti di ricerca internazionali e nazionali, ammessi al finanziamento sulla base di bandi competitivi** che prevedano la revisione tra pari, sono di seguito riportati i principali:

Progetto

AIFA 2005: FARM5C4FB4 - An open-label, multicenter, randomized phase III study of second-line chemotherapy with or without bevacizumab in metastatic colorectal cancer patients who have received first-line chemotherapy plus bevacizumab. Ruolo Ricoperto: Promotore, Co-investigator.

PRIN 2010: Ottimizzazione dei trattamenti personalizzati con le terapie con farmaci a bersaglio molecolare nel cancro del colon retto. Responsabile Unità: Prof. Alfredo Falcone - Università degli Studi di Pisa. Coordinatore Scientifico: Prof. Fortunato CIARDIELLO, Seconda Università di Napoli (euro 932.000 complessivi; euro 140.000 per unità di appartenenza). Ruolo Ricoperto: Partecipante Unità Clinica.

AIRC (Associazione Italiana per la Ricerca sul Cancro) 2009: The role of chemotherapy in antiangiogenic drug resistance: a main actor or an extra? (euro 183.000). Ruolo Ricoperto: Responsabile Unità Clinica.

ITT (Istituto Toscano Tumori) - Regione Toscana 2010: Antiangiogenic drug resistance and chemotherapy (euro 220.500). Ruolo Ricoperto: Responsabile Unità Clinica.

Nell'Ottobre 2007 è stato eletto rappresentante nazionale del **Working Group AIOM Giovani** dell'Associazione Italiana di Oncologia Medica, incarico che ha ricoperto fino all'Ottobre 2011.

Dal Giugno 2012 è **Coordinatore dell'Ufficio Sperimentazioni Cliniche** del Polo Oncologico Area Vasta Nord-Ovest.

**Pubblicazioni Scientifiche su Riviste Peer-Reviewed e con Impact Factor**

	<b>Title - Authors - Journal</b>	<b>Year</b>	<b>2015 IF</b>
148.	Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Murgioni S, Rossini D, Marmorino F, Mennitto A, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Yamaguch T, <b>Loupakis F</b> , Lenz HJ. Ann Oncol. 2017 May 1;28(5):1015-1022 PMID: 28184423.	2017	9.269
147.	QoL is a cool tool. Procaccio L, Lonardi S, <b>Loupakis F</b> , Di Maio M. Ann Oncol. 2017 Apr 18. doi: 10.1093/annonc/mdx199. [Epub ahead of print] No abstract available. PMID: 28430888	2017	9.269
146.	Immunotherapy for colorectal cancer: where are we heading? Basile D, Garattini SK, Bonotto M, Ongaro E, Casagrande M, Cattaneo M, Fanotto V, De Carlo E, <b>Loupakis F</b> , Urbano F, Negri FV, Pella N, Russano M, Brunetti O, Scartozzi M, Santini D, Silvestris N, Casadei Gardini A, Puzzone M, Calvetti L, Cardarelli N, Aprile G. Expert Opin Biol Ther. 2017 Apr 4. PMID: 28375039.	2017	3.438
145.	Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. Schirripa M, Zhang W, Heinemann V, Cao S, Okazaki S, Yang D, <b>Loupakis F</b> , Berger MD, Ning Y, Miyamoto Y, Suenaga M, Gopez RF, West JD, Hanna D, Barzi A, Falcone A, Stintzing S, Lenz HJ. Int J Cancer. 2017 Apr 1. PMID: 28369940.	2017	5.531
144.	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, Cremolini C, Falcone A, Heinemann V, <b>Loupakis F</b> , Stintzing S, Lenz HJ. Eur J Cancer. 2017 Mar 24;77:13-20. PMID: 28347919.	2017	6.163
143.	Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients. Carbone C, Piro G, Simionato F, Ligorio F, Cremolini C, <b>Loupakis F</b> , Alì G, Rossini D, Merz V, Santoro R, Zecchetto C, Zanotto M, Di Nicolantonio F, Bardelli A, Fontanini G, Tortora G, Melisi D. Clin Cancer Res. 2017 Mar 15. [Epub ahead of print] PMID: 28298545.	2017	8.738
142.	The role of pharmacogenetics in the new ESMO colorectal cancer guidelines.	2017	2.710

- Schirripa M, Procaccio L, Lonardi S, **Loupakis F**.  
Pharmacogenomics. 2017 Feb;18(3):197-200.  
PMID: 28112993.
141. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. 2017 5.569  
Marmorino F, Salvatore L, Barbara C, Allegrini G, Antonuzzo L, Masi G, **Loupakis F**, Borelli B, Chiara S, Banzi MC, Miraglio E, Amoroso D, Dargenio F, Bonetti A, Martignetti A, Paris M, Tomcikova D, Boni L, Falcone A, Cremolini C.  
Br J Cancer. 2017 Jan 12;116(3):318-323.  
PMID: 28081548.
140. Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer. 2017 1.895  
Pasqualetti F, Montrone S, Vivaldi C, Zani M, Fedele D, Fornaro L, Pasqualetti G, Salvatore L, Manfredi B, Laliscia C, Coraggio G, Gonnelli A, **Loupakis F**, Masi G, Sainato A, Monzani F, Falcone A, Paiar F.  
Anticancer Res. 2017 Jan;37(1):315-319.  
PMID: 28011508.
139. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. 2016 6.163  
Cremolini C, Casagrande M, **Loupakis F**, Aprile G, Bergamo F, Masi G, Moretto R R, Pietrantonio F, Marmorino F, Zucchelli G, Tomasello G, Tonini G, Allegrini G, Granetto C, Ferrari L, Urbani L, Cillo U, Pilati P, Sensi E, Pellegrinelli A, Milione M, Fontanini G, Falcone A.  
Eur J Cancer. 2016 Dec 13.  
PMID: 27986363.
138. Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. 2016 9.269  
Pietrantonio F, Miceli R, Rimassa L, Lonardi S, Aprile G, Mennitto A, Marmorino F, Bozzarelli S, Antonuzzo L, Tamburini E, Morano F, Rossini D, Battaglin F, Baretta M, Berenato R, Formica V, Mosconi S, Petrelli F, Ghidini M, **Loupakis F**, Spada D, Cinieri S, Beretta G, Falcone A, de Braud F, Cremolini C.  
Ann Oncol. 2016 Nov 17.  
PMID: 27864220.
137. Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. 2016 4.245  
Cremolini C, Antoniotti C, Pietrantonio F, Berenato R, Tampellini M, Baratelli C, Salvatore L, Marmorino F, Borelli B, Nichetti F, Bironzo P, Sonetto C, Bartolomeo MD, de Braud F, **Loupakis F**, Falcone A, Maio MD.  
Cancer Res Treat. 2016 Nov 15.  
PMID: 27857020.
136. Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients. 2016 2.152  
Paolicchi E, Vivaldi C, De Gregorio V, Crea F, Fornaro L, Masi G, **Loupakis F**, Graziano F, Ronzoni M, Ricci V, Falcone A, Danesi R.

- Oncology. 2016 Aug 31.  
PMID: 27577551.
135. CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. 2016 3.784  
Matsusaka S, Cao S, Hanna DL, Sunakawa Y, Ueno M, Mizunuma N, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Stremitzer S, Yamauchi S, Parekh A, Okazaki S, Berger MD, El-Khoueiry R, Mendez A, Ichikawa W, **Loupakis F**, Lenz HJ.  
Pharmacogenomics J. 2016 Aug 9.  
PMID: 27503580.
134. Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. 2016 4.789  
Moretto R, Cremolini C, Rossini D, Pietrantonio F, Battaglin F, Mennitto A, Bergamo F, **Loupakis F**, Marmorino F, Berenato R, Marsico VA, Caporale M, Antoniotti C, Masi G, Salvatore L, Borelli B, Fontanini G, Lonardi S, De Braud F, Falcone A.  
Oncologist. 2016 Jul 5.  
PMID: 27382031.
133. CDX2 as a Prognostic Biomarker in Colon Cancer. 2016 59.558  
Schirripa M, **Loupakis F**, Lenz HJ.  
N Engl J Med. 2016 Jun 2;374(22):2183  
PMID: 27248629.
132. Clinical significance of TLR1 I602S polymorphism for patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab. 2016 5.579  
Okazaki S, **Loupakis F**, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Stremitzer S, Matsusaka S, Berger MD, Parekh A, West JD, Miyamoto Y, Suenaga M, Schirripa M, Cremolini C, Falcone A, Heinemann V, DePaolo RW, Lenz HJ.  
Mol Cancer Ther. 2016 May 11  
PMID: 27196764.
131. Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the lab. 2016 9.269  
Sartore-Bianchi A, **Loupakis F**, Argilés G, Prager GW.  
Ann Oncol. 2016 May 6.  
PMID: 27154421.
130. Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. 2016 2.488  
Aprile G, Ferrari L, Cremolini C, Bergamo F, Fontanella C, Battaglin F, Rihawi K, Lonardi S, **Loupakis F**, Scartozzi M.  
Expert Rev Clin Pharmacol. 2016 May 5.  
PMID: 27149032.
129. Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. 2016 5.228  
Giampieri R, Salvatore L, Del Prete M, Prochilo T, D'Anzeo M, Loretelli C, **Loupakis F**, Aprile G, Maccaroni E, Andrikou K, Bianconi M, Bittoni A, Faloppi L, Demurtas L, Montironi R, Scarpelli M,



- Falcone A, Zaniboni A, Scartozzi M, Cascinu S.  
 Sci Rep. 2016 Apr 27;6:25195. doi: 10.1038/srep25195.  
 PMID: 27117754.
128. Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. 2016 3.784  
 Falvella FS, Cremolini C, Miceli R, Nichetti F, Cheli S, Antoniotti C, Infante G, Martinetti A, Marmorino F, Sottotetti E, Berenato R, Caporale M, Colombo A, de Braud F, Di Bartolomeo M, Clementi E, **Loupakis F**, Pietrantonio F.  
 Pharmacogenomics J. 2016 Mar 22. doi: 10.1038/tpj.2016.22. [Epub ahead of print]  
 PMID: 27001121.
127. Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer. 2016 3.784  
 Graziano F, Ruzzo A, Giacomini E, Ricciardi T, Aprile G, **Loupakis F**, Lorenzini P, Ongaro E, Zoratto F, Catalano V, Sarti D, Rulli E, Cremolini C, De Nictolis M, De Maglio G, Falcone A, Fiorentini G, Magnani M.  
 Pharmacogenomics J. 2016 Mar 1.  
 PMID: 26927284.
126. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. 2016 9.269  
 Cremolini C, **Loupakis F**, Masi G, Lonardi S, Granetto C, Mancini ML, Chiara S, Moretto R, Rossini D, Vitello S, Allegrini G, Tonini G, Bergamo F, Tomasello G, Ronzoni M, Buonadonna A, Bustreo S, Barbara C, Boni L, Falcone A.  
 Ann Oncol. 2016 Feb 9.  
 PMID: 26861604.
125. Prognostic Impact of IL-6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. 2016 8.738  
 Matsusaka S, Hanna DL, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Okazaki S, Berger MD, Miyamoto Y, Parekh A, Stintzing S, **Loupakis F**, Lenz HJ.  
 Clin Cancer Res. 2016 Feb 2.  
 PMID: 26839145.
124. A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer. 2015 3.197  
**Loupakis F**, Stein A, Ychou M, Hermann F, Salud A, Österlund P.  
 Target Oncol. 2015 Dec 19.  
 PMID: 26687849.
123. TRIBE study: are all three cytotoxic drugs crucial? - Authors' reply. 2015 26.509  
**Loupakis F**, Cremolini C, Rossini D, Falcone A.  
 Lancet Oncol. 2015 Dec;16(16):e578-9. doi: 10.1016/S1470-2045(15)00416-7. No abstract available.  
 PMID: 26678196.

122. Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. 2015 5.569  
**Loupakis F**, Moretto R, Aprile G, Muntoni M, Cremolini C, Iacono D, Casagrande M, Ferrari L, Salvatore L, Schirripa M, Rossini D, De Maglio G, Fasola G, Calvetti L, Pilotto S, Carbognin L, Fontanini G, Tortora G, Falcone A, Sperduti I, Bria E.  
 Br J Cancer. 2015 Nov 17.  
 PMID: 26575603.
121. Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. 2015 3.265  
 Fornaro L, Faviana P, De Gregorio V, Vivaldi C, Paolicchi E, Masi G, **Loupakis F**, Sensi E, Lupi C, Fontanini G, Wang Y, Danesi R, Falcone A, Crea F.  
 BMC Cancer. 2015 Nov 9;15:874.  
 PMID: 26553291.
120. TAS-102 for the treatment of metastatic colorectal cancer. 2015 2.094  
 Salvatore L, Rossini D, Moretto R, Cremolini C, Schirripa M, Antoniotti C, Marmorino F, **Loupakis F**, Falcone A, Masi G.  
 Expert Rev Anticancer Ther. 2015 Oct 28:1-10.  
 PMID: 26509228.
119. Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. 2015 20.982  
 Renfro LA, **Loupakis F**, Adams RA, Seymour MT, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ.  
 J Clin Oncol. 2015 Oct 26.  
 PMID: 26503203.
118. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. 2015 5.485  
 Valtorta E, Martino C, Sartore-Bianchi A, Penault-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Bencardino K, Lonardi S, Zagonel V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, **Loupakis F**, Racca P, Tonini G, Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M.  
 Mod Pathol. 2015 Oct 9.  
 PMID: 26449765.
117. Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. 2015 4.789  
 Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A, Mennitto A, Berenato R, Antoniotti C, Casagrande M, Marsico V, Marmorino F, Cardellino GG, Bergamo F, Tomasello G, Formica V, Longarini R, Giommoni E, Caporale M, Di Bartolomeo M, **Loupakis F**, de Braud F.  
 Oncologist. 2015 Oct 7. [Epub ahead of print]  
 PMID: 26446234.
116. TAS-102, a novel antitumor agent: A review of the mechanism of 2015 7.983

action.

Lenz HJ, Stintzing S, **Loupakis F**.

Cancer Treat Rev. 2015 Jun 6. [Epub ahead of print] Review.

PMID: 26428513.

115. Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: Results from TRIBE and FIRE3 trials. 2015 9.269  
Sunakawa Y, Stintzing S, Cao S, Heinemann V, Cremolini C, Falcone A, Yang D, Zhang W, Ning Y, Stremitzer S, Matsusaka S, Yamauchi S, Parekh A, Okazaki S, Berger MD, Graver S, Mendez A, Scherer SJ, **Loupakis F**, Lenz HJ.  
Ann Oncol. 2015 Sep 28.  
PMID 26416897.
114. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. 2015 5.008  
Vincenzi B, Cremolini C, Sartore-Bianchi A, Russo A, Mannavola F, Perrone G, Pantano F, **Loupakis F**, Rossini D, Ongaro E, Bonazzina E, Dell'Aquila E, Imperatori M, Zoccoli A, Bronte G, De Maglio G, Fontanini G, Natoli C, Falcone A, Santini D, Onetti-Muda A, Siena S, Tonini G, Aprile G.  
Oncotarget. 2015 Aug 19.  
PMID 26384309.
113. Phase II study of single agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. 2015 9.269  
Schirripa M, **Loupakis F**, Lonardi S, Cremolini C, Bergamo F, Zagonel V, Falcone A.  
Ann Oncol. 2015 Sep 14. pii: mdv385. [Epub ahead of print] No abstract available.  
PMID 26371285.
112. BRAF-mutated metastatic colorectal cancer between past and future. 2015 5.569  
Cremolini C, Di Maio M, Petrelli F, Berenato R, **Loupakis F**, Pietrantonio F.  
Br J Cancer. 2015 Sep 10.  
PMID 26355234.
111. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. 2015 26.509  
Cremolini C, **Loupakis F**, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A.  
Lancet Oncol. 2015 Aug 28. [Epub ahead of print]  
PMID: 26338525.
110. Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management. 2015 5.008  
Del Prete MD, Giampieri R, **Loupakis F**, Prochilo T, Salvatore L, Faloppi L, Bianconi M, Bittoni A, Aprile G, Zaniboni A, Falcone A, Scartozzi M, Cascinu S.

- Oncotarget. 2015 Aug 17. [Epub ahead of print]  
PMID: 26334693.
109. Response. 2015 13.757  
Cremolini C, **Loupakis F**, Lenz HJ.  
J Natl Cancer Inst. 2015 Aug 1;107(10).  
PMID: 26232792.
108. First-line chemotherapy for mCRC-a review and evidence-based algorithm. 2015 18.786  
Cremolini C, Schirripa M, Antoniotti C, Moretto R, Salvatore L, Masi G, Falcone A, **Loupakis F**.  
Nat Rev Clin Oncol. 2015 Jul 28. Review.  
PMID: 26215044.
107. Polymorphisms in genes involved in EGFR-turnover are predictive for cetuximab efficacy in colorectal cancer. 2015 5.579  
Stintzing S, Zhang W, Heinemann V, Neureiter D, Kemmerling R, Kirchner T, Jung A, Folwaczny M, Yang D, Ning Y, Sebio A, Stremitzer S, Sunakawa Y, Matsusaka S, Yamauchi S, **Loupakis F**, Cremolini C, Falcone A, Lenz HJ.  
Mol Cancer Ther. 2015 Jul 23.  
PMID: 26206335.
106. Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology. 2015 1.071  
Aurilio G, Gori S, Nolè F, Pruneri G, Coati F, Torri V, Lunardi G, Atzori F, Verde N, Banna GL, Rossi A, Mastro LD, Fabio FD, Marcon I, Gebbia V, **Loupakis F**, Orlando L, Ciuffreda L, Amadio P, Luppi G, Redana S, Filippelli G, Gentile A, Collovà E.  
Tumori. 2015 Jul 2;0(0):0.  
PMID: 26166216.
105. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. 2015 9.269  
Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S, Sartore-Bianchi A, Fontanini G, Milione M, Lauricella C, Siena S, Falcone A, de Braud F, **Loupakis F**, Pietrantonio F.  
Ann Oncol. 2015 Jul 7. pii: mdv290. [Epub ahead of print]  
PMID: 26153495.
104. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. 2015 5.039  
Pietrantonio F, Cremolini C, Petrelli F, Di Bartolomeo M, **Loupakis F**, Maggi C, Antoniotti C, de Braud F, Falcone A, Iacovelli R.  
Crit Rev Oncol Hematol. 2015 Jun 5.  
PMID:26088456.
103. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. 2015 30.357  
Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A,

- Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, **Loupakis F**, Siena S, Sartore-Bianchi A, Bardelli A.  
Nat Med. 2015 Jun 1.  
PMID: 26030179.
102. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. 2015 5.569  
Schirripa M, Bergamo F, Cremolini C, Casagrande M, Lonardi S, Aprile G, Yang D, Marmorino F, Pasquini G, Sensi E, Lupi C, De Maglio G, Borrelli N, Pizzolitto S, Fasola G, Bertorelle R, Rugge M, Fontanini G, Zagonel V, **Loupakis F**, Falcone A.  
Br J Cancer. 2015 May 5.  
PMID: 25942399.
101. Bevacizumab and First-line Chemotherapy for Older Patients with Advanced Colorectal Cancer: Final Results of a Community-based Observational Italian Study. 2015 1.895  
Lutrino SE, Bergamo F, Schirripa M, Rosati G, Avallone A, Giampieri R, Cordio S, Berretta M, Llimpe FR, Pisa FE, Lonardi S, **Loupakis F**, Fasola G, Aprile G.  
Anticancer Res. 2015 Apr;35(4):2391-9.  
PMID: 25862905.
100. Primary tumor location as a prognostic factor in metastatic colorectal cancer. 2015 13.757  
**Loupakis F**, Yang D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ, Müller T, Hurwitz HI, Saltz L, Falcone A, Lenz HJ.  
J Natl Cancer Inst. 2015 Feb 24;107(3).  
PMID: 25713148
99. Early Tumor Shrinkage and Depth of Response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. 2015 9.269  
Cremolini C, **Loupakis F**, Antoniotti C, Lonardi S, Masi G, Salvatore L, Cortesi E, Tomasello G, Spadi R, Zaniboni A, Tonini G, Barone C, Vitello S, Longarini R, Bonetti A, D'Amico M, Di Donato S, Granetto C, Boni L, Falcone A.  
Ann Oncol. 2015 Feb 23.  
PMID: 25712456
98. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. 2015 9.269  
Masi G, Salvatore L, Boni L, **Loupakis F**, Cremolini C, Fornaro L, Schirripa M, Cupini S, Barbara C, Safina V, Granetto C, Fea E, Antonuzzo L, Boni C, Allegrini G, Chiara S, Amoroso D, Bonetti A, Falcone A; on behalf of the BEBYP Study Investigators.  
Ann Oncol. 2015 Jan 18.  
PMID: 25600568
97. FOLFOXIRI and bevacizumab for metastatic colorectal cancer. 2015 59.558  
Cremolini C, **Loupakis F**, Falcone A.  
N Engl J Med. 2015 Jan 15;372(3):291-2.  
PMID: 25587960

96. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. 2015 3.784  
Maus MK, Hanna DL, Stephens CL, Astrow SH, Yang D, Grimminger PP, **Loupakis F**, Hsiang JH, Zeger G, Wakatsuki T, Barzi A, Lenz HJ.  
Pharmacogenomics J. 2014 Dec 23.  
PMID: 25532759
95. Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. 2015 3.784  
Bohanes P, Yang D, **Loupakis F**, LaBonte MJ, Gerger A, Ning Y, Lenz C, Lenz F, Wakatsuki T, Zhang W, Benhaim L, El-Khoueiry A, El-Khoueiry R, Lenz HJ.  
Pharmacogenomics J. 2014 Dec 9.  
PMID: 25487679
94. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. 2015 3.438  
Silvestris N, Scartozzi M, Graziano G, Santini D, Lorusso V, Maiello E, Barni S, Cinieri S, **Loupakis F**, Pisconti S, Brunetti AE, Palasciano G, Palmieri VO, Del Prete M, Dell'Aquila E, Latiano TP, Petrelli F, Lutrino S, Rossini D, Giampieri R, Lotesoriere C, Cascinu S.  
Expert Opin Biol Ther. 2015 Feb;15(2):155-62.  
PMID: 25411089
93. Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. 2014 2.710  
Silvestris N, Vincenzi B, Brunetti AE, **Loupakis F**, Dell'Aquila E, Russo A, Scartozzi M, Giampieri R, Cascinu S, Lorusso V, Tonini G, Falcone A, Santini D.  
Pharmacogenomics. 2014 Sep;15(13):1701-15.  
PMID: 25410895
92. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. 2014 59.558  
**Loupakis F**, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A.  
N Engl J Med. 2014 Oct 23;371(17):1609-18.  
PMID: 25337750
91. Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ER $\alpha$ -positive advanced breast cancer. 2014 3.784  
Benhaim L, Zhang W, Wakatsuki T, Yang D, Gerger A, Bohanes P, Paez D, **Loupakis F**, LaBonte MJ, Ning Y, El-Khoueiry R, Ladner R, Wilson P, Zhang H, Giamas G, Stebbing J, Lenz HJ.  
Pharmacogenomics J. 2014 Oct 7.  
PMID: 25287073
90. Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. 2014 3.784  
Volz NB, Stintzing S, Zhang W, Yang D, Ning Y, Wakatsuki T, El-Khoueiry RE, Li JE, Kardosh A, **Loupakis F**, Cremolini C, Falcone A,

- Scherer SJ, Lenz HJ.  
Pharmacogenomics J. 2014 Jul 29.  
PMID: 25069475
89. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. 2014 14.921  
Geva R, Vecchione L, Kalogerias KT, Vittrup Jensen B, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, **Loupakis F**, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S.  
Gut. 2014 Jul 10.  
PMID: 25011934
88. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. 2014 5.531  
Schirripa M, Cremolini C, **Loupakis F**, Morvillo M, Bergamo F, Zoratto F, Salvatore L, Antoniotti C, Marmorino F, Sensi E, Lupi C, Fontanini G, Gregorio VD, Giannini R, Basolo F, Masi G, Falcone A.  
Int J Cancer. 2014 May 8.  
PMID: 24806288
87. KRAS and BRAF genotyping of synchronous colorectal carcinomas. 2014 1.482  
Giannini R, Lupi C, **Loupakis F**, Servadio A, Cremolini C, Sensi E, Chiarugi M, Antoniotti C, Basolo F, Falcone A, Fontanini G.  
Oncol Lett. 2014 May;7(5):1532-1536. Epub 2014 Feb 21.  
PMID: 24765171
86. Biomarkers and response to bevacizumab. 2014 8.738  
Cremolini C, **Loupakis F**, Bocci G, Falcone A.  
Clin Cancer Res. 2014 Feb 15;20(4):1056-7.  
PMID: 24536076
85. Prospective study of EGFR intron 1 (CA)(n) repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. 2014 3.784  
**Loupakis F**, Antoniotti C, Cremolini C, Zhang W, Yang D, Wakatsuki T, Bohanes P, Schirripa M, Salvatore L, Masi G, Ricci V, Graziano F, Ruzzo A, Benhaim L, Marmorino F, Ning Y, El-Khoueiry R, Falcone A, Lenz HJ.  
Pharmacogenomics J. 2014 Feb 11.  
PMID: 24513691
84. Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab' 2013 5.569  
Schirripa M, **Loupakis F**, Pollina L, Cremolini C, Pasquini G, Falcone A.  
Br J Cancer. 2013 Oct 24.  
PMID: 24157829
83. A perspective on the current management of advanced colorectal cancer. 2013 2.129  
Casagrande M, Cremolini C, **Loupakis F**, Aprile G.

- Future Oncol. 2013 Nov;9(11):1687-91.  
PMID: 24156327
82. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. 2013 6.163  
**Loupakis F**, Cremolini C, Salvatore L, Masi G, Sensi E, Schirripa M, Michelucci A, Pfanner E, Brunetti I, Lupi C, Antoniotti C, Bergamo F, Lonardi S, Zagonel V, Simi P, Fontanini G, Falcone A.  
Eur J Cancer. 2013 Oct 15.  
PMID: 24138831
81. Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. 2013 5.579  
Wakatsuki T, Labonte MJ, Bohanes PO, Zhang W, Yang D, Azuma M, Barzi A, Ning Y, **Loupakis F**, Saadat S, Volz N, Stintzing S, El-Khoueiry R, Koizumi W, Watanabe M, Shah M, Stebbing J, Giamas G, Lenz HJ.  
Mol Cancer Ther. 2013 Oct;12(10):2261-72.  
PMID: 23918832
80. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. 2013 3.057  
**Loupakis F**, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, Bohanes P, Schirripa M, Benhaim L, Lonardi S, Antoniotti C, Aprile G, Graziano F, Ruzzo A, Lucchesi S, Ronzoni M, De Vita F, Tonini G, Falcone A, Lenz HJ.  
PLoS One. 2013 Jul 4;8(7):e66774.  
PMID: 23861747
79. Liquid biopsy: monitoring cancer-genetics in the blood. 2013 18.786  
Crowley E, Di Nicolantonio F, **Loupakis F**, Bardelli A.  
Nat Rev Clin Oncol. 2013 Aug;10(8):472-84.  
PMID: 23836314
78. EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. 2013 3.197  
**Loupakis F**, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Schirripa M, Di Desidero T, Antoniotti C, Canu B, Faviana P, Sensi E, Lupi C, Fontanini G, Basolo F, Di Paolo A, Danesi R, Falcone A, Bocci G.  
Target Oncol. 2013 Jul 3. [Epub ahead of print]  
PMID: 23821377
77. Association of common gene variants in the WNT/ $\beta$ -catenin pathway with colon cancer recurrence. 2013 2.710  
Páez D, Gerger A, Zhang W, Yang D, Labonte MJ, Benhaim L, Kahn M, Lenz F, Lenz C, Ning Y, Wakatsuki T, **Loupakis F**, Lenz HJ.  
Pharmacogenomics J. 2013 Jul 2.  
PMID: 23817222
76. Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 2013 3.090  
Brandi G, Derenzini E, Falcone A, Masi G, **Loupakis F**, Pietrabissa A, Pinna AD, Ercolani G, Pantaleo MA, Di Girolamo S, Grazi GL, de



Rosa F, Biasco G.  
 Clin Colorectal Cancer. 2013 Sep;12(3):188-94.  
 PMID: 23773458

75. Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy. 2013 3.784  
 Benhaim L, Gerger A, Bohanes P, Paez D, Wakatsuki T, Yang D, Labonte MJ, Ning Y, El-Khoueiry R, **Loupakis F**, Zhang W, Laurent-Puig P, Lenz HJ.  
 Pharmacogenomics J. 2013 Jun 11.  
 PMID: 23752739
74. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. 2013 5.569  
**Loupakis F**, Schirripa M, Caparello C, Funel N, Pollina L, Vasile E, Cremolini C, Salvatore L, Morvillo M, Antoniotti C, Marmorino F, Masi G, Falcone A.  
 Br J Cancer. 2013 Jun 25;108(12):2549-56.  
 PMID: 23703247
73. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 2013 9.269  
 Fornaro L, Lonardi S, Masi G, **Loupakis F**, Bergamo F, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile G, Zaniboni A, Bracarda S, Fontanini G, Sensi E, Lupi C, Morvillo M, Zagonel V, Falcone A.  
 Ann Oncol. 2013 May 10.  
 PMID: 23666916
72. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. 2013 3.784  
 Negri FV, Musolino A, Naldi N, Bortesi B, Missale G, Laccabue D, Zerbini A, Camisa R, Chernyschova N, Bisagni G, **Loupakis F**, Ruzzo A, Neri TM, Ardizzoni A.  
 Pharmacogenomics J. 2013 Jan 8.  
 PMID: 23296156
71. Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis. 2012 5.531  
 Roy UK, Henkhaus RS, **Loupakis F**, Cremolini C, Gerner EW, Ignatenko NA.  
 Int J Cancer. 2012 Dec 22. doi: 10.1002/ijc.28001. [Epub ahead of print]  
 PMID: 23280667
70. Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients. 2012 6.163  
 Vincenzi B, Zoccoli A, Schiavon G, Iuliani M, Pantano F, Dell'aquila E, Ratta R, Muda AO, Perrone G, Brunelli C, Correale P, Riva E, Russo A, **Loupakis F**, Falcone A, Santini D, Tonini G.  
 Eur J Cancer. 2012 Dec 21. [Epub ahead of print]  
 PMID: 23266047
69. Selecting the best targeted agent in first-line treatment of 2012 3.146

- unresectable liver metastases from colorectal cancer: does the bench have the answers?  
 Benhaim L, **Loupakis F**, Labonte MJ, Lenz HJ.  
 J Hepatobiliary Pancreat Sci. 2012 Sep;19(5):528-35.  
 PMID: 22735932 [PubMed - in process]
68. Influence of Sex on the Survival of Patients With Esophageal Cancer. 2012 20.982  
 Bohanes P, Yang D, Chhibar RS, Labonte MJ, Winder T, Ning Y, Gerger A, Benhaim L, Paez D, Wakatsuki T, **Loupakis F**, El-Khoueiry R, Zhang W, Lenz HJ.  
 J Clin Oncol. 2012 May 14. [Epub ahead of print]  
 PMID: 22585694
67. High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease. 2012 4.789  
 Ruzzo A, Graziano F, Vincenzi B, Canestrari E, Perrone G, Galluccio N, Catalano V, **Loupakis F**, Rabitti C, Santini D, Tonini G, Fiorentini G, Rossi D, Falcone A, Magnani M.  
 Oncologist. 2012 May 14
66. Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer. 2012 3.141  
 Manzoni M, Mariucci S, Delfanti S, Rovati B, Ronzoni M, **Loupakis F**, Brugnattelli S, Tinelli C, Villa E, Falcone A, Danova M.  
 J Cancer Res Clin Oncol. 2012 Mar 15. [Epub ahead of print]  
 PMID: 22419441
65. EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. 2012 9.269  
 Fornaro L, Crea F, Masi G, Paolicchi E, **Loupakis F**, Graziano F, Salvatore L, Ronzoni M, Ricci V, Cremolini C, Schirripa M, Danesi R, Falcone A.  
 Ann Oncol. 2012 Mar 7.  
 PMID: 22383679
64. Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. 2012 4.301  
 Allegrini G, Di Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, Chericoni S, **Loupakis F**, Di Paolo A, Masi G, Fontana A, Lucchesi S, Arrighi G, Giusiani M, Ciardo A, Brandi G, Danesi R, Kerbel RS, Falcone A, Bocci G.  
 Angiogenesis. 2012 Mar 2.  
 PMID: 22382585
63. The possible role of chemotherapy in antiangiogenic drug resistance. 2012 1.136  
 Bocci G, **Loupakis F**.  
 Med Hypotheses. 2012 Feb 24.  
 PMID: 22365648
62. "HER Majesty's a Pretty Nice Girl but She Changes From Day to Day". 2012 20.982

Bohanes P, **Loupakis F**, Labonte MJ, Wakatsuki T, Lenz HJ.  
 J Clin Oncol. 2012 Feb 1;30(4):465-6.  
 PMID: 22203763

- |     |  |      |       |
|-----|--|------|-------|
| 61. | Cancer dormancy: a model of early dissemination and late cancer recurrence.<br>Páez D, Labonte MJ, Bohanes P, Zhang W, Benhanim L, Ning Y, Wakatsuki T, <b>Loupakis F</b> , Lenz HJ.<br>Clin Cancer Res. 2012 Feb 1;18(3):645-53.<br>PMID: 22156560  | 2012 | 8.738 |
| 60. | Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.<br>Scartozzi M, Giampieri R, Maccaroni E, Mandolesi A, Giustini L, Silva R, Zaniboni A, Biscotti T, Biagetti S, Galizia E, <b>Loupakis F</b> , Falcone A, Bearzi I, Cascinu S.<br>Ann Oncol. 2011 Nov 23.<br>PMID: 22112971 | 2011 | 9.269 |
| 59. | Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: Meta-analytical estimation and implications for therapeutic strategies.<br><b>Loupakis F</b> , Cremolini C, Salvatore L, Schirripa M, Lonardi S, Vaccaro V, Cuppone F, Giannarelli D, Zagonel V, Cognetti F, Tortora G, Falcone A, Bria E.<br>Cancer. 2011 Aug 25.<br>PMID: 22009364   | 2011 | 5.649 |
| 58. | An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.<br>Crea F, Fornaro L, Paolicchi E, Masi G, Frumento P, <b>Loupakis F</b> , Salvatore L, Cremolini C, Schirripa M, Graziano F, Ronzoni M, Ricci V, Farrar WL, Falcone A, Danesi R.<br>Ann Oncol. 2011 Sep 16.<br>PMID: 21926398  | 2011 | 9.269 |
| 57. | Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen.<br>Fornaro L, Vasile E, Masi G, <b>Loupakis F</b> , Baldi GG, Allegrini G, Salvatore L, Cremolini C, Cupini S, Cortesi E, Tuzi A, Granetto C, Brunetti IM, Ricci S, Falcone A.<br>Clin Colorectal Cancer. 2011 Sep 6.<br>PMID: 21903485  | 2011 | 3.090 |
| 56. | Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle.<br>Bocci G, <b>Loupakis F</b> .<br>Pharmacogenomics. 2011 Aug;12(8):1077-80.<br>PMID: 21843059  | 2011 | 2.710 |
| 55. | Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.  | 2011 | 3.265 |

- Loupakis F**, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, Schirripa M, Catalano V, Galluccio N, Canestrari E, Vincenzi B, Santini D, Bencardino K, Ricci V, Manzoni M, Danova M, Tonini G, Magnani M, Falcone A, Graziano F.  
BMC Cancer. 2011 Jun 14;11:247.  
PMID: 21669012
54. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. 2011 5.569  
Scartozzi M, Bearzi I, Mandolesi A, Giampieri R, Faloppi L, Galizia E, **Loupakis F**, Zaniboni A, Zorzi F, Biscotti T, Labianca R, Falcone A, Cascinu S.  
Br J Cancer. 2011 May 10.  
PMID: 21559018
53. Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. 2011 9.269  
Catalano V, **Loupakis F**, Graziano F, Bisonni R, Torresi U, Vincenzi B, Mari D, Giordani P, Alessandrini P, Salvatore L, Fornaro L, Santini D, Baldelli AM, Rossi D, Giustini L, Silva RR, Falcone A, D'Emidio S, Rocchi M, Luzi Fedeli S.  
Ann Oncol. 2011 Apr 29.  
PMID: 21531784
52. PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. 2011 3.839  
Vincenzi B, Santini D, Perrone G, Graziano F, **Loupakis F**, Schiavon G, Frezza AM, Ruzzo AM, Rizzo S, Crucitti P, Galluzzo S, Zoccoli A, Rabitti C, Muda AO, Russo A, Falcone A, Tonini G.  
J Cell Physiol. 2011 Apr 18. [Epub ahead of print]  
PMID: 21503888
51. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. 2011 5.569  
**Loupakis F**, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Di Desidero T, Canu B, Schirripa M, Frumento P, Di Paolo A, Danesi R, Falcone A, Bocci G.  
Br J Cancer. 2011 Mar 15. [Epub ahead of print]  
PMID: 21407216
50. Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer. 2011 2.422  
Manzoni M, Rovati B, Ronzoni M, **Loupakis F**, Mariucci S, Ricci V, Gattoni E, Salvatore L, Tinelli C, Villa E, Danova M.  
Oncology. 2011 Feb 28;79(3-4):187-196  
PMID: 21358206
49. Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer. 2011 3.743  
**Loupakis F**, Cremolini C, Schirripa M, Masi G, Falcone A.  
Expert Opin Biol Ther. 2011 Jan 27. [Epub ahead of print]  
PMID: 21269235

48. Should Oncologists Be Aware in Their Clinical Practice of KRAS Molecular Analysis? 2011 20.982  
Santini D, Galluzzo S, Gaeta L, Zoccoli A, Riva E, Ruzzo A, Vincenzi B, Graziano F, **Loupakis F**, Falcone A, Muda AO, Tonini G.  
J Clin Oncol. 2011 Jan 24.  
PMID: 21263083
47. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. 2011 13.757  
Masi G, Vasile E, **Loupakis F**, Cupini S, Fornaro L, Baldi G, Salvatore L, Cremolini C, Stasi I, Brunetti I, Fabbri MA, Puglisi M, Trenta P, Granetto C, Chiara S, Fioretto L, Allegrini G, Crinò L, Andreuccetti M, Falcone A.  
J Natl Cancer Inst. 2011 Jan 5;103(1):21-30.  
PMID: 21123833
46. Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. 2010 9.269  
Vincenzi B, Galluzzo S, Santini D, Rocci L, **Loupakis F**, Correale P, Addeo R, Zoccoli A, Napolitano A, Graziano F, Ruzzo A, Falcone A, Francini G, Dicuonzo G, Tonini G.  
Ann Oncol. 2010 Nov 29.  
PMID: 21115601
45. Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. 2010 2.710  
Graziano F, Ruzzo A, Canestrari E, Catalano V, Santini D, Galluccio N, **Loupakis F**, Alessandrini P, Spada D, Ficarelli R, Bissoni R, D'Emidio S, Vincenzi B, Angeletti S, Salvatore L, Cremolini C, Tonini G, Falcone A, Magnani M.  
Pharmacogenomics. 2010 Sep;11(9):1247-56.  
PMID: 20860465
44. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. 2010 26.509  
Masi G, **Loupakis F**, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A.  
Lancet Oncol. 2010 Sep;11(9):845-52. Epub 2010 Aug 9.  
PMID: 20702138
43. Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target. 2009 0.488  
Scartozzi M, Bearzi I, Mandolesi A, Galizia E, Pierantoni C, **Loupakis F**, Berardi R, Zaniboni A, Quadri A, Zorzi F, Biagetti S, Loretelli C, Biscotti T, Labianca R, Masi G, Falcone A, Cascinu S.  
Anal Quant Cytol Histol. 2009 Dec;31(6):417-23.  
PMID: 20698358
42. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status. 2010 4.027

Fornaro L, Baldi GG, Masi G, Allegrini G, **Loupakis F**, Vasile E, Cupini S, Stasi I, Salvatore L, Cremolini C, Vincenzi B, Santini D, Tonini G, Graziano F, Ruzzo A, Canestrari E, Magnani M, Falcone A.  
 Crit Rev Oncol Hematol. 2010 Jul 7.

- |     |   |      |        |
|-----|---|------|--------|
| 41. | <p>High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice.</p> <p>Santini D, Spoto C, <b>Loupakis F</b>, Vincenzi B, Silvestris N, Cremolini C, Canestrari E, Graziano F, Galluccio N, Salvatore L, Caraglia M, Zito FA, Colucci G, Falcone A, Tonini G, Ruzzo A.</p> <p>Ann Oncol. 2010 Jul;21(7):1565.<br/>       PMID: 20573852</p>   | 2010 | 9.269  |
| 40. | <p>Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials.</p> <p><b>Loupakis F</b>, Bria E, Vaccaro V, Cuppone F, Milella M, Carlini P, Cremolini C, Salvatore L, Falcone A, Muti P, Sperduti I, Giannarelli D, Cognetti F.</p> <p>J Exp Clin Cancer Res. 2010 May 26;29:58.<br/>       PMID: 20504361</p>   | 2010 | 4.429  |
| 39. | <p>Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients.</p> <p>Ronzoni M, Manzoni M, Mariucci S, <b>Loupakis F</b>, Brugnatelli S, Bencardino K, Rovati B, Tinelli C, Falcone A, Villa E, Danova M.</p> <p>Ann Oncol. 2010 Dec;21(12):2382-9. Epub 2010 May 23.<br/>       PMID: 20497963</p>   | 2010 | 9.269  |
| 38. | <p>Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?</p> <p><b>Loupakis F</b>, Falcone A.</p> <p>Nat Rev Clin Oncol. 2010 Apr;7(4):190-1.<br/>       PMID: 20354542</p>  | 2010 | 18.786 |
| 37. | <p>Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.</p> <p><b>Loupakis F</b>, Masi G, Fornaro L, Vasile E, Allegrini G, Fontana E, Granetto C, Salvatore L, Mentuccia L, Andreuccetti M, Cortesi E, Merlano M, Cascinu S, Falcone A.</p> <p>Cancer Chemother Pharmacol. 2010 Aug;66(3):559-66. Epub 2010 Mar 17.<br/>       PMID: 20237927</p> | 2010 | 2.769  |
| 36. | <p>Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.</p> <p>Graziano F, Canestrari E, <b>Loupakis F</b>, Ruzzo A, Galluccio N, Santini D, Rocchi M, Vincenzi B, Salvatore L, Cremolini C, Spoto C, Catalano V, D'Emidio S, Giordani P, Tonini G, Falcone A, Magnani M.</p>   | 2010 | 3.784  |

- Pharmacogenomics J. 2010 Oct;10(5):458-64.  
PMID: 20177422
35. Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "TranslationAL"? 2010 20.982  
Cremolini C, **Loupakis F**, Ruzzo A, Perrone G, Rulli E, Vincenzi B, Tonini G, Graziano F, Muda AO, Falcone A.  
J Clin Oncol. 2010 Apr 10;28(11):e173-4.  
PMID: 20177018
34. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. 2010 5.531  
Scartozzi M, Mandolesi A, Giampieri R, Pierantoni C, **Loupakis F**, Zaniboni A, Galizia E, Giustini L, Silva RR, Bissoni R, Berardi R, Biagetti S, Menzo S, Falcone A, Bearzi I, Cascinu S.  
Int J Cancer. 2010 Oct 15;127(8):1941-7.  
PMID: 20099280
33. Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients. 2010 3.522  
**Loupakis F**, Bocci G, Pasqualetti G, Fornaro L, Salvatore L, Cremolini C, Masi G, Danesi R, Del Tacca M, Falcone A.  
Curr Cancer Drug Targets. 2010 Feb 1;10(1):37-45.  
PMID: 20088795
32. Palliative treatment of unresectable metastatic colorectal cancer. 2010 3.534  
Fornaro L, Masi G, **Loupakis F**, Vasile E, Falcone A.  
Expert Opin Pharmacother. 2010 Jan;11(1):63-77. Review.  
PMID: 20001430
31. Capecitabine after gastrectomy for advanced gastric cancer: have we got the patient right? 2010 9.269  
Fornaro L, Vasile E, Masi G, **Loupakis F**, Caponi S, Ginocchi L, Falcone A.  
Ann Oncol. 2010 Jan;21(1):181. Epub 2009 Nov 4.  
PMID: 19889616
30. Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. 2009 2.827  
**Loupakis F**, Cremolini C, Fontanini G, Stasi I, Salvatore L, Falcone A.  
Ther Adv Med Oncol. 2009 Nov;1(3):167-81.  
PMID: 21789120
29. Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine. 2009 18.786  
Masi G, Fornaro L, Cupini S, **Loupakis F**, Vasile E, Baldi GG, Stasi I, Salvatore L, Falcone A.  
Nat Rev Clin Oncol. 2009 Nov;6(11):670-4.  
PMID: 19861994
28. Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and

chromogenic in situ hybridization (CISH) analysis.

Scartozzi M, Bearzi I, Mandolesi A, Pierantoni C, **Loupakis F**, Zaniboni A, Negri F, Quadri A, Zorzi F, Galizia E, Berardi R, Biscotti T, Labianca R, Masi G, Falcone A, Cascinu S.

BMC Cancer. 2009 Aug 27;9:303.

PMID: 19712476

27. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. 2009 5.569
- Loupakis F**, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F.
- Br J Cancer. 2009 Aug 18;101(4):715-21. Epub 2009 Jul 14.  
PMID: 19603018
26. Do we need biopsies of metastases for colorectal cancer patients? 2009 5.569
- Floriani I, Santini D, Torri V, Cremolini C, Falcone A, **Loupakis F**.
- Br J Cancer. 2009 Jul 21;101(2):374-5; author reply 376. Epub 2009 Jul 7.  
PMID: 19584870
25. Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. 2009 3.743
- Vincenzi B, Santini D, **Loupakis F**, Addeo R, Rojas Llimpe FL, Baldi GG, Di Fabio F, Del Prete S, Pinto C, Falcone A, Tonini G.
- Expert Opin Biol Ther. 2009 Aug;9(8):945-9.  
PMID: 19534585
24. Chemotherapy and immunotherapy in metastatic colorectal cancer. 2009 59.558
- Loupakis F**, Di Maio M, Falcone A.
- N Engl J Med. 2009 May 14;360(20):2135; author reply 2135-6.  
PMID: 19445032
23. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. 2009 5.569
- Vasile E, Masi G, Fornaro L, Cupini S, **Loupakis F**, Bursi S, Petrini I, Di Donato S, Brunetti IM, Ricci S, Antonuzzo A, Chiara S, Amoroso D, Andreuccetti M, Falcone A.
- Br J Cancer. 2009 Jun 2;100(11):1720-4.  
PMID: 19436300
22. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. 2009 20.982
- Loupakis F**, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A.
- J Clin Oncol. 2009 Jun 1;27(16):2622-9.  
PMID: 19398573



21. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. 2009 5.569  
Catalano V, **Loupakis F**, Graziano F, Torresi U, Bisonni R, Mari D, Fornaro L, Baldelli AM, Giordani P, Rossi D, Alessandroni P, Giustini L, Silva RR, Falcone A, D'Emidio S, Fedeli SL.  
Br J Cancer. 2009 Mar 24;100(6):881-7. Epub 2009 Mar 3.  
PMID: 19259089
20. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. 2009 8.327  
Masi G, **Loupakis F**, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi F, Pietrabissa A, Goletti O, Baldi G, Fornaro L, Andreuccetti M, Falcone A.  
Ann Surg. 2009 Mar;249(3):420-5.  
PMID: 19247029
19. Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. 2009 3.784  
Graziano F, Ruzzo A, Canestrari E, **Loupakis F**, Santini D, Rulli E, Humar B, Galluccio N, Bisonni R, Floriani I, Maltese P, Falcone A, Tonini G, Catalano V, Fontana A, Giustini L, Masi G, Vincenzi B, Alessandroni P, Magnani M.  
Pharmacogenomics J. 2009 Feb;9(1):78-84. Epub 2008 Dec 23.  
PMID: 19104506
18. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. 2009 4.789  
Santini D, **Loupakis F**, Vincenzi B, Floriani I, Stasi I, Canestrari E, Rulli E, Maltese PE, Andreoni F, Masi G, Graziano F, Baldi GG, Salvatore L, Russo A, Perrone G, Tommasino MR, Magnani M, Falcone A, Tonini G, Ruzzo A.  
Oncologist. 2008 Dec;13(12):1270-5. Epub 2008 Dec 4.  
PMID: 19056857
17. Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. 2009 3.878  
Bocci G, Di Paolo A, Barbara C, Masi G, Fornaro L, **Loupakis F**, Allegrini G, Falcone A, Del Tacca M, Danesi R.  
Br J Clin Pharmacol. 2009 Jan;67(1):132-4. Epub 2008 Nov 5.  
PMID: 19006547
16. Optimal approach to potentially resectable liver metastases from colorectal cancer. 2008 2.094  
Falcone A, Fornaro L, **Loupakis F**, Masi G, Vasile E.  
Expert Rev Anticancer Ther. 2008 Oct;8(10):1533-9. Review.  
PMID: 18925845
15. A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. 2009 2.769  
Fornaro L, Masi G, Bursi S, **Loupakis F**, Vasile E, Antonuzzo A, Chiara S, Pfanner E, Di Paolo A, Bocci G, Del Tacca M, Falcone A.

- Cancer Chemother Pharmacol. 2009 Apr;63(5):965-9. Epub 2008 Oct 7.  
PMID: 18839174
14. VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. 2009 2.449  
Maltese P, Canestrari E, Ruzzo A, Graziano F, Falcone A, **Loupakis F**, Tonini G, Santini D, Magnani M.  
Int J Colorectal Dis. 2009 Feb;24(2):165-70. Epub 2008 Oct 2.  
PMID: 18830612
13. Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. 2008 5.569  
Graziano F, Ruzzo A, **Loupakis F**, Santini D, Catalano V, Canestrari E, Maltese P, Bissoni R, Fornaro L, Baldi G, Masi G, Falcone A, Tonini G, Giordani P, Alessandroni P, Giustini L, Vincenzi B, Magnani M.  
Br J Cancer. 2008 Sep 2;99(5):716-21. Epub 2008 Aug 12.  
PMID: 18728661
12. First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first? 2008 4.614  
**Loupakis F**, Masi G, Vasile E, Falcone A.  
Curr Opin Oncol. 2008 Jul;20(4):459-65. Review.  
PMID: 18525344
11. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 2008 5.569  
Allegrini G, Falcone A, Fioravanti A, Barletta MT, Orlandi P, **Loupakis F**, Cerri E, Masi G, Di Paolo A, Kerbel RS, Danesi R, Del Tacca M, Bocci G.  
Br J Cancer. 2008 Apr 22;98(8):1312-9. Epub 2008 Mar 25.  
PMID: 18362940
10. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. 2008 20.982  
Graziano F, Ruzzo A, **Loupakis F**, Canestrari E, Santini D, Catalano V, Bissoni R, Torresi U, Floriani I, Schiavon G, Andreoni F, Maltese P, Rulli E, Humar B, Falcone A, Giustini L, Tonini G, Fontana A, Masi G, Magnani M.  
J Clin Oncol. 2008 Mar 20;26(9):1427-34.  
PMID: 18349392
9. Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer. 2008 3.090  
Masi G, Vasile E, **Loupakis F**, Bursi S, Ricci S, Petrini I, Fontana A, Allegrini G, Falcone A.  
Clin Colorectal Cancer. 2008 Jan;7(1):7-14. Review.  
PMID: 18279572
8. EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. 2008 2.710  
**Loupakis F**, Vasile E, Santini D, Masi G, Falcone A, Graziano F.  
Pharmacogenomics. 2008 Jan;9(1):55-69. Review.  
PMID: 18154448

- |    |  |      |        |
|----|--|------|--------|
| 7. | <p>Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.</p> <p>Scartozzi M, Bearzi I, Pierantoni C, Mandolesi A, <b>Loupakis F</b>, Zaniboni A, Catalano V, Quadri A, Zorzi F, Berardi R, Biscotti T, Labianca R, Falcone A, Cascinu S.</p> <p>J Clin Oncol. 2007 Sep 1;25(25):3930-5.<br/>PMID: 17761976</p>  | 2007 | 20.982 |
| 6. | <p>Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.</p> <p>Ruzzo A, Graziano F, <b>Loupakis F</b>, Santini D, Catalano V, Bisonni R, Ficarelli R, Fontana A, Andreoni F, Falcone A, Canestrari E, Tonini G, Mari D, Lippe P, Pizzagalli F, Schiavon G, Alessandrini P, Giustini L, Maltese P, Testa E, Menichetti ET, Magnani M.</p> <p>Pharmacogenomics J. 2008 Aug;8(4):278-88. Epub 2007 Jun 5.<br/>PMID: 17549067</p> | 2008 | 3.784  |
| 5. | <p>Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity.</p> <p><b>Loupakis F</b>, Falcone A, Masi G, Fioravanti A, Kerbel RS, Del Tacca M, Bocci G.</p> <p>J Clin Oncol. 2007 May 1;25(13):1816-8.<br/>PMID: 17470880</p>  | 2007 | 20.982 |
| 4. | <p>Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.</p> <p>Ruzzo A, Graziano F, <b>Loupakis F</b>, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M.</p> <p>J Clin Oncol. 2007 Apr 1;25(10):1247-54.<br/>PMID: 17401013</p>  | 2007 | 20.982 |
| 3. | <p>Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?</p> <p>Gelibter AJ, Lonardi S, Di Segni S, Fontana A, <b>Loupakis F</b>, Cognetti F, Labianca R.</p> <p>J Clin Oncol. 2006 Oct 1;24(28):4668-9.<br/>PMID: 17008710</p>  | 2006 | 20.982 |
| 2. | <p>First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.</p> <p>Masi G, Marcucci L, <b>Loupakis F</b>, Cerri E, Barbara C, Bursi S, Allegrini G, Brunetti IM, Murr R, Ricci S, Cupini S, Andreuccetti M, Falcone A.</p> <p>Ann Oncol. 2006 Aug;17(8):1249-54.<br/>PMID: 16766580</p>  | 2006 | 9.269  |
| 1. | <p>Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.</p> <p>Masi G, Cupini S, Marcucci L, Cerri E, <b>Loupakis F</b>, Allegrini G, Brunetti IM, Pfanner E, Viti M, Goletti O, Filipponi F, Falcone A.</p> <p>Ann Surg Oncol. 2006 Jan;13(1):58-65. Epub 2006 Jan 1.</p>   | 2006 | 3.655  |

PMID: 16372158